Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized double-blind study of EP-0226 versus pregabalin and placebo in postherpetic neuralgia
CTR20263676Phase 3Active
- Sponsor
- Chengdu Easton Biopharmaceuticals Co., Ltd.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of EP-0226 in postherpetic neuralgia (PHN), sponsored by Chengdu Easton Biopharmaceuticals Co., Ltd.. Started Oct 2026; status: active.
02
Drugs
EP-0226
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on CTR20263676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263676.